These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26909147)

  • 1. Preclinical animal models of multiple myeloma.
    Lwin ST; Edwards CM; Silbermann R
    Bonekey Rep; 2016; 5():772. PubMed ID: 26909147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.
    Paton-Hough J; Chantry AD; Lawson MA
    Bone; 2015 Aug; 77():57-68. PubMed ID: 25868800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal Models of Multiple Myeloma Bone Disease.
    Mehdi SH; Nafees S; Mehdi SJ; Morris CA; Mashouri L; Yoon D
    Front Genet; 2021; 12():640954. PubMed ID: 34163520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):967-72. PubMed ID: 17956671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Pain-Related Behaviors and Bone Disease in Immunocompetent Mouse Models of Myeloma.
    Diaz-delCastillo M; Kamstrup D; Olsen RB; Hansen RB; Pembridge T; Simanskaite B; Jimenez-Andrade JM; Lawson MA; Heegaard AM
    JBMR Plus; 2020 Feb; 4(2):e10252. PubMed ID: 32083236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
    Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
    Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.
    Xu L; Mohammad KS; Wu H; Crean C; Poteat B; Cheng Y; Cardoso AA; Machal C; Hanenberg H; Abonour R; Kacena MA; Chirgwin J; Suvannasankha A; Srour EF
    Cancer Res; 2016 Dec; 76(23):6901-6910. PubMed ID: 27634757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.
    Reagan MR; Liaw L; Rosen CJ; Ghobrial IM
    Bone; 2015 Jun; 75():161-9. PubMed ID: 25725265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of animal models in multiple myeloma.
    Libouban H
    Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
    Neri P; Bahlis NJ; Lonial S
    Clin Cancer Res; 2016 Dec; 22(24):5959-5965. PubMed ID: 27797968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.
    Thirukkumaran CM; Shi ZQ; Nuovo GJ; Luider J; Kopciuk KA; Dong Y; Mostafa AA; Thakur S; Gratton K; Yang A; Chin AC; Coffey MC; Jimenez-Zepeda VH; Stewart D; Chesi M; Bergsagel PL; Morris D
    Blood Adv; 2019 Mar; 3(5):797-812. PubMed ID: 30850386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
    Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
    Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Evidence-Based Approach to Myeloma Bone Disease.
    Bingham N; Reale A; Spencer A
    Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
    Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; King P; Vande Broek I; De Raeve H; Van Camp B; Croucher P; Vanderkerken K
    Leukemia; 2009 Oct; 23(10):1894-903. PubMed ID: 19494837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma biology: lessons from the 5TMM models.
    Vanderkerken K; Asosingh K; Croucher P; Van Camp B
    Immunol Rev; 2003 Aug; 194():196-206. PubMed ID: 12846816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A murine model of human myeloma bone disease.
    Garrett IR; Dallas S; Radl J; Mundy GR
    Bone; 1997 Jun; 20(6):515-20. PubMed ID: 9177864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
    Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
    Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.